UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009634
Receipt number R000010813
Scientific Title Phase II/III study of Gemcitabine and S-1 (GS therapy) as Neoadjuvant chemotherapy for resectable pancreatic cancer (Prep-02/JSAP-05)
Date of disclosure of the study information 2012/12/26
Last modified on 2019/07/04 09:22:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II/III study of Gemcitabine and S-1 (GS therapy) as Neoadjuvant chemotherapy for resectable pancreatic cancer (Prep-02/JSAP-05)

Acronym

Neoadjuvant GS therapy for pancreatic cancer : Prep-02/JSAP-05

Scientific Title

Phase II/III study of Gemcitabine and S-1 (GS therapy) as Neoadjuvant chemotherapy for resectable pancreatic cancer (Prep-02/JSAP-05)

Scientific Title:Acronym

Neoadjuvant GS therapy for pancreatic cancer : Prep-02/JSAP-05

Region

Japan


Condition

Condition

Resectable pancreatic cancer

Classification by specialty

Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Phase II: To evaluate the equivalence of safety and resection rate for neoadjuvant GS therapy comparing standard therapy.
Phase III: To evaluate superiority in survival of neoadjuvant GS therapy against standard surgery-first therapy in patients with resectable pancreatic cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II,III


Assessment

Primary outcomes

Phase II: Resection rate
Phase III: Overall survival

Key secondary outcomes

Phase II: Adverse events
Phase III: Adverse events, Resection rate, Residual tumor, Nodal involvement rate, Histological response, Relapse-free survival, Tumor marker kinetics, Dose intensity, Patterns of Recurrence, Radiological tumor response


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Neoadjuvant chemotherapy with gemcitabine and S-1 followed by surgery and adjuvant with 4 course of oral S-1 (Test arm).

Interventions/Control_2

Surgery and adjuvant with 4 course of oral S-1 (Control arm).

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

79 years-old >=

Gender

Male and Female

Key inclusion criteria

1) invasive ductal carcinoma of the pancreas
2) no distant metastasis
3) R0/1 resectable
4) all adult who anticipate to undergo pancreatectomy
5) no prior therapy
6) written informed consent
6) ECOG performance status of 0 or 1
7) Adequate organ function
8) Written informed consent

Key exclusion criteria

1) pulmonary fibrosis or interstitial pneumonitis
2) Uncontrolled watery diarrhea
3) Active double cancer
4) Active infection
5) HBs antigen positive
6) Pregnant females, possibly pregnant females

Target sample size

360


Research contact person

Name of lead principal investigator

1st name Michiaki
Middle name
Last name Unno

Organization

Tohoku University Graduate School of Medicine

Division name

Division of gastroenterological surgery

Zip code

980-8574

Address

1-1, Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan

TEL

022-717-7205

Email

m_unno@surg.med.tohoku.ac.jp


Public contact

Name of contact person

1st name Fuyuhiko
Middle name
Last name Motoi

Organization

Tohoku University Graduate School of Medicine

Division name

Surgery

Zip code

980-8574

Address

1-1, Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan

TEL

022-717-7205

Homepage URL

http://www.surg.med.tohoku.ac.jp/society/prep02.html

Email

fmotoi@surg.med.tohoku.ac.jp


Sponsor or person

Institute

Study group of preoperative therapy for pancreatic cancer (PREP)/Japanese Study Group of Adjuvant Therapy for pancreatic Cancer (JSAP)

Institute

Department

Personal name



Funding Source

Organization

Ministry of Health, Labour and Welfare

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB of Tohoku Univ.

Address

1-1, Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan

Tel

022-717-8007

Email

rinri-2@proj.med.tohoku.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 12 Month 26 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

https://meetinglibrary.asco.org/record/169433/abstract

Number of participants that the trial has enrolled

364

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2012 Year 12 Month 26 Day

Date of IRB

2012 Year 11 Month 27 Day

Anticipated trial start date

2013 Year 01 Month 04 Day

Last follow-up date

2019 Year 01 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 12 Month 26 Day

Last modified on

2019 Year 07 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010813


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name